BAYER Supplement: Diabetic Macular Edema

Chairman’s Introduction

Prof Jean-François Korobelnik MD, chief of the Ophthalmology Department, University Hospital (CHU) Bordeaux, France, chaired Bayer Healthcare’s Satellite Symposium “DME: When Every Letter Counts” held on 12 September at the 14th EURETINA Congress in London, United Kingdom.

“Early diagnosis of diabetic macular edema (DME) is critical, and if not treated rigorously, there is a high risk of serious loss of visual function or even blindness,” said Prof Korobelnik. The good news, however, is that clinicians now have an additional tool to add to their treatment armamentarium with the recent approval
by the European Commission of Eylea® (aflibercept solution for injection) for the treatment of visual impairment due to DME.

“The results of two phase III studies were very encouraging with the majority of patients with visual impairment due to DME experiencinga significant two-line improvement in visual acuity with aflibercept solution for injection,” Prof Korobelnik said. Discussing the approved European protocol, he explained that Eylea® is recommended at 2.0mg, equivalent to 50 microlitres, with the treatment for DME initiated with one injection per month for five consecutive doses, followed by one injection every two months.

Download Supplement